Active Ingredient(s): Eribulin Mesylate
FDA Approved: * November 15, 2010
Pharm Company: * EISAI INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Halaven Overview

Eribulin, sold under the brand name Halaven, is an anticancer medication used to treat breast cancer and liposarcoma.[2][4] The most common side effects include fatigue, nausea, hair loss (alopecia), constipation, certain nerve damage causing weakness or numbness in the hands and feet (peripheral neuropathy), abdominal pain and fever (pyrexia).[7] Eribulin may also cause low levels of infection-fighting white blood cells (neutropenia) or decreas...

Read more Halaven Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Eribulin

Recent Halaven Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Eribulin Mesylate
  • Solution: 1mg/2ml (0.5mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Halaven: (2 results)

Sorted by National Drug Code
  • 43624-002 Halaven .5 mg/ml Intravenous Injection by Bsp Pharmaceuticals Spa
  • 62856-389 Halaven .5 mg/ml Intravenous Injection by Eisai Inc.

Other drugs which contain Eribulin Mesylate or a similar ingredient: (1 result)